Depomed

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Depomed, Inc.
Public company
Traded as NASDAQDEPO
Industry Pharmaceutical Industry
Founded 1995 (1995)
Headquarters Newark, California
Products Pharmaceuticals
Revenue DecreaseUS$342.7 million (2015)[1]
DecreaseUS$-50.4 million (2015)[1]
DecreaseUS$-75.7 million (2015)[1]
Total assets IncreaseUS$1.3 billion (2015)[1]
Total equity DecreaseUS$315 million (2015)[1]
Number of employees
494 (December 2015)[2]
Website www.depomed.com

Depomed, Inc. is an American specialty pharmaceutical company which mainly markets products for treatment in neurology, pain and diseases of the central nervous system.[3] Depomed was founded in 1995 and is headquartered in Newark, California.[4] The company is a publicly traded company on NASDAQ under the symbol "DEPO", with several products approved by the United States Food and Drug Administration (FDA).

Products[edit]

The company's products include Nucynta ER, Nucynta, Gralise, Cambia, Lazanda, Zipsor, and DM-1992, which mainly focus on pain, neuropathic pain, and central nervous system diseases.[3]

For Pain[edit]

Nucynta ER, Nucynta IR

On January 15, 2015, Depomed announced the acquisition of the Nucynta franchise from Janssen Pharmaceutica for US$1,050,000,000 in cash. The transaction closed on April 2, 2015, and the products are scheduled to be relaunched in June 2015 after a major salesforce expansion.

Gralise

In January 2011, Gralise once-daily (gabapentin extended release) was approved by the US FDA for the treatment of postherpetic neuralgia.[5] The drug has also received Orphan Drug designation from the FDA.

For diabetes and others[edit]

The company's diabetes treatment, Glumetza (metformin hydrochloride extended release tablet), was approved for the treatment of type II diabetes in adults, and is sold in the US by Valeant.[6]

Corporate affairs[edit]

Acquisition[edit]

In June 2012, all rights to Zipsor Liquid Filled Capsules was acquired by Depomed from Xanodyne Pharmaceuticals, revenue generated by Zipsor was approximately US$19,000,000 as within the twelve months from Jun 2011 to May 2012.[7]

Lawsuits[edit]

In March 2012, the company filed a patent infringement lawsuit against three companies that had filed Abbreviated New Drug Applications with the US FDA, claiming infringement of Depomed's six US patents listed for Gralise in the FDA's Orange Book.[8]

References[edit]

External links[edit]